Literature DB >> 3336392

Myocardial infarction in a patient with hemophilia treated with DDAVP.

L Bond, D Bevan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3336392

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 2.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

3.  Cerebral venous thrombosis associated with thyrotoxicosis, the use of desmopressin and elevated factor VIII/von Willebrand factor.

Authors:  Waqar Waheed; Salman Aljerdi; Barbara Decker; Mary Cushman; Robert W Hamill
Journal:  BMJ Case Rep       Date:  2016-08-08

Review 4.  Desmopressin (DDAVP) and hemostasis.

Authors:  S Lethagen
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Correction of coagulopathy for percutaneous interventions.

Authors:  Charles Wiltrout; Kimi L Kondo
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

Review 6.  Pharmacological management of renal colic in the older patient.

Authors:  Blayne K Welk; Joel M H Teichman
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Budd-Chiari syndrome, ascites and shunt malfunction due to hyperosmolar hypernatremia in operated pediatric craniopharyngiomas: a red herring.

Authors:  Sunil V Furtado; P K Dash; K Reddy; A S Hegde
Journal:  Childs Nerv Syst       Date:  2008-03-19       Impact factor: 1.475

8.  Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini; Giancarlo Castaman; Augusto B Federici
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

9.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

Authors:  Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

Review 10.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.